Big Pharma Antibiotic Pipelines Shrink 35% in Five Years
Major drugmakers reduced antimicrobial development programs from 92 to 60 over five years, raising alarm over the global response to antibiotic resistance.
Technology & Innovation
Robert Kim is a biomedical engineer at the University of Hawaii Cancer Center with a focus on medical device development and computational approaches to clinical data. He covers medical technology, AI in medicine, digital health platforms, and telemedicine advances for Hawaii Medical Journal.
Major drugmakers reduced antimicrobial development programs from 92 to 60 over five years, raising alarm over the global response to antibiotic resistance.